Clinical Trial Update: Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated the safety and tolerability of ciclesonide nasal spray in children aged 2-5 with perennial allergic rhinitis; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Rhinitis

Drugs mentioned

• Ciclesonide nasal spray (ciclesonide)

Snippet

Sponsor: AstraZeneca | Conditions: Hay Fever, Perennial Allergic Rhinitis | Phase 3 | Status: COMPLETED